Corvus Pharmaceuticals Statistics
Want to see CRVS full AI Analyst Report?
Corvus Pharmaceuticals (CRVS) Stock Statistics & Valuation Metrics
Total Valuation
Corvus Pharmaceuticals has a market cap or net worth of $844.37M. The enterprise value is $863.15M.
- Market Cap
- $844.37M
- Enterprise Value
- $863.15M
Share Statistics
Corvus Pharmaceuticals has 84,353,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 84,353,130
- Owned by Insiders
- 13.80%
- Owned by Institutions
- 74.31%
Financial Efficiency
Corvus Pharmaceuticals’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -69.15%.
- Return on Equity (ROE)
- -0.25
- Return on Assets (ROA)
- -0.21
- Return on Invested Capital (ROIC)
- -69.15%
- Return on Capital Employed (ROCE)
- -0.70
- Revenue Per Employee
- 0
- Profits Per Employee
- -413.05K
- Employee Count
- 37
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Corvus Pharmaceuticals is -13.53. Corvus Pharmaceuticals’s PEG ratio is 0.08.
- PE Ratio
- -13.53
- PS Ratio
- 0.00
- PB Ratio
- 4.44
- Price to FCF
- -17.61
- Price to Operating Cash Flow
- -19.62
- PEG Ratio
- 0.08
Income Statement
In the last 12 months, Corvus Pharmaceuticals had revenue of 0 and earned -15.28M in profits. Earnings per share was -0.19.
- Revenue
- 0
- Gross Profit
- -105.00K
- Operating Income
- -42.97M
- Pretax Income
- -15.28M
- Net Income
- -15.28M
- EBITDA
- -15.18M
- Earnings Per Share (EPS)
- -0.19
Cash Flow
In the last 12 months, operating cash flow was -47.18M and capital expenditures -764,000, giving a free cash flow of -47.94M billion.
- Operating Cash Flow
- -47.18M
- Free Cash Flow
- -47.94M
- Free Cash Flow per Share
- -0.52
Dividends & Yields
Corvus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.62%
- Earnings Yield
- -6.87%
Stock Price Statistics
- Beta
- 0.93
- 52-Week Price Change
- 12.47%
- 50-Day Moving Average
- 11.03
- 200-Day Moving Average
- 13.79
- Relative Strength Index (RSI)
- 42.95
- Average Volume (3m)
- 1.04M
Important Dates
Corvus Pharmaceuticals upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Corvus Pharmaceuticals as a current ratio of 6.21, with Debt / Equity ratio of 1.53%
- Current Ratio
- 6.21
- Quick Ratio
- 6.21
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.24
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Corvus Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Corvus Pharmaceuticals EV to EBITDA ratio is -13.55, with an EV/FCF ratio of -17.51.
- EV to Sales
- 0.00
- EV to EBITDA
- -13.55
- EV to Free Cash Flow
- -17.51
- EV to Operating Cash Flow
- -17.79
Balance Sheet
Corvus Pharmaceuticals has $202.95M in cash and marketable securities with $632.00K in debt, giving a net cash position of $202.31M billion.
- Cash & Marketable Securities
- $202.95M
- Total Debt
- $632.00K
- Net Cash
- $202.31M
- Net Cash Per Share
- $2.40
- Tangible Book Value Per Share
- $2.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Corvus Pharmaceuticals is $28.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $28.75
- Price Target Upside
- 187.21% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -272.40%
Scores
- Smart Score
- 8
- AI Score
- 51

